Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The strong heart study

Journal of the American College of Cardiology

Volumn 40, Issue 11, 2002, Pages 1984-1990

  Levy, Andrew P ^a   Hochberg, Irit ^a   Jablonski, Kathleen ^b   Resnick, Helaine E ^b   Lee, Elisa T ^c   Best, Lyle ^d   Howard, Barbara V ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN;

ADULT; ALGORITHM; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL RESEARCH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GLOBIN GENE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPTOGLOBINS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0037021557     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02534-2     Document Type: Article

References (28)

1. Howard BV, Magee MF. Diabetes and cardiovascular disease. Curr Atheroscler Rep 2000;2:476-81.
2. Aronson D, Rayfield EJ. Diabetes, In: Topol EJ, editor. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven, 1998:171-94.
3. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: Therapeutic options in patients with diabetes. J Am Coll Card 2000;36:355-65.
4. UK Prospective Diabetes Study Group. Ethnicity and cardiovascular disease: The incidence of myocardial infarction in white, south Asian and afro-Caribbean patients with type 2 diabetes. Diabetes Care 1998;21:1271-7.
5. Bowman BH, Kurosky A. Haptoglobin: The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genetics 1982;12:189-261.
6. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-600.
7. Maeda N, Smithies O. The evolution of multigene families: Human haptoglobin genes. Ann Rev Genetics 1986;20:81-108.
8. Delanghe J, Langlois M, Ouyang J, Claeys G, De Buyzere M, Wuyts B. Effect of haptoglobin phenotypes on growth of Streptococcus pyogenes. Clin Chem Lab Med 1998;36:691-6.
9. Giblett ER. Genetic Markers in Human Blood. Oxford: Blackwell Scientific, 1969;63-125.
10. Melamed-Frank M, Lache O, Enav BI, Rickliss R, Levy AP. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood 2001;98:3693-8.
11. Levy AP, Roguin A, Hochberg I, et al. Haptoglobin phenotype and vascular complications in diabetes. N Eng J Med 2000;343:969-70.
12. Nakhoul F, Marsh S, Hochberg I, Leibu R, Miller BP, Levy AP. Haptoglobin phenotype and diabetic retinopathy. JAMA 2000;284:1244-5.
13. Nakhoul F, Zoabi R, Kantor Y, et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001;44:602-4.
14. Roguin A, Hochberg I, Nikolsky E, et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 2001;87:330-2.
15. Delanghe J, Cambier B, Langlois M, De Buyzere ML, Bernard DR, Ouyang J. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 1997;132:215-9.
16. Chapelle JP, Albert A, Smeets JP, Marechal JP, Heusghem C, Kulbertus HE. Effect of the haptoglobin phenotype on the size of a myocardiai infarct. N Engl J Med 1982;307:457-63.
17. DeBacquer D, DeBacker G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001;157:161-6.
18. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians: The Strong Heart study. Circ 1999;99:2389-95.
19. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart study: Design and methods. Am J Epidemiol 1990;132:1141-55.
20. Howard BV, Welty TK, Fabsitz R, et al. Risk factors for coronary heart disease in diabetic and nondiabetic North Americans: The Strong Heart study. Diabetes 1992;41:4-11.
21. WHO Expert Committee on Diabetes Mellitus. Second Report (technical report series 646). Geneva: World Health Organization, 1980.
22. Lee ET, Cowan LD, Welty TK, et al. All cause mortality and cardiovascular disease mortality in 3 American Indian populations aged 45 to 74 years, 1984 to 88: The Strong Heart study. Am J Epidemiol 1998;147:995-1008.
23. Howard BV, Lee ET, Cowan LD, et al. Coronary heart disease prevalence and its relation to risk factors in American Indians: The Strong Heart study. Am J Epidemiol 1995;142:254-68.
24. Smithies O. Zone electrophoresis in starch gels: Group variations in the serum proteins of normal human adults. Biochemistry 1955;61:629-41.
25. Hochberg I, Roguin A, Nikolsky E, Chanderaskekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002;161:441-6.
26. Hamad M, Awadallah S. Age group associated variations in the pattern of Hp type distribution in Jordan. Clin Chim Acta 2000;300:75-81.
27. Teisberg P, Gjone E, Olaisen B. Genetics of lecithin: Cholesterol acyltransferase deficiency. Ann Hum Genetics 1975;38:327-40.
28. Guigliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.